The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells

dc.contributor.author
Sorianello, Eleonora
dc.contributor.author
Zaragoza, Francesc X. (Francesc Xavier)
dc.contributor.author
Fernández Pascual, Sergio
dc.contributor.author
Sancho Medina, Ana
dc.contributor.author
Naón Elbirt, Déborah P.
dc.contributor.author
Vila Caballer, Marian
dc.contributor.author
González Navarro, Herminia
dc.contributor.author
Portugal, José, 1954-
dc.contributor.author
Andrés García, Vicente
dc.contributor.author
Palacín Prieto, Manuel
dc.contributor.author
Zorzano Olarte, Antonio
dc.date.issued
2014-12-16T13:40:05Z
dc.date.issued
2014-12-16T13:40:05Z
dc.date.issued
2012-04-01
dc.date.issued
2014-12-16T13:40:05Z
dc.identifier
0008-6363
dc.identifier
https://hdl.handle.net/2445/60798
dc.identifier
618477
dc.description.abstract
AIMS: Mitofusin-2 (Mfn2) expression is dysregulated in vascular proliferative disorders and its overexpression attenuates the proliferation of vascular smooth muscle cells (VSMCs) and neointimal lesion development after balloon angioplasty. We sought to gain insight into the mechanisms that control Mfn2 expression in VSMCs. METHODS AND RESULTS: We cloned and characterized 2 kb of the 5'-flanking region of the human Mfn2 gene. Its TATA-less promoter contains a CpG island. In keeping with this, 5'-rapid amplification of cDNA ends revealed six transcriptional start sites (TSSs), of which TSS2 and TSS5 were the most frequently used. The strong CpG island was found to be non-methylated under conditions characterized by large differences in Mfn2 gene expression. The proximal Mfn2 promoter contains six putative Sp1 motifs. Sp1 binds to the Mfn2 promoter and its overexpression activates the Mfn2 promoter in VSMCs. Chemical inhibition of Sp1 reduced Mfn2 expression, and Sp1 silencing reduced transcriptional activity of the Mfn2 promoter. In keeping with this view, Sp1 and Mfn2 mRNA levels were down-regulated in the aorta early after an atherogenic diet in apolipoprotein E-knockout mice or in VSMCs cultured in the presence of low serum. CONCLUSION: Sp1 is a key factor in maintaining basal Mfn2 transcription in VSMCs. Given the anti-proliferative actions of Mfn2, Sp1-induced Mfn2 transcription may represent a mechanism for prevention of VSMC proliferation and neointimal lesion and development.
dc.format
47 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Oxford University Press
dc.relation
Versió postprint del document publicat a: http://dx.doi.org/10.1093/cvr/cvs006
dc.relation
Cardiovascular Research, 2012, vol. 94, num. 1, p. 38-47
dc.relation
http://dx.doi.org/10.1093/cvr/cvs006
dc.rights
(c) European Society of Cardiology, 2012
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
dc.subject
Metabolisme cel·lular
dc.subject
Transcripció genètica
dc.subject
Proteïnes
dc.subject
Malalties cardiovasculars
dc.subject
Cell metabolism
dc.subject
Genetic transcription
dc.subject
Proteins
dc.subject
Cardiovascular diseases
dc.title
The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.